The Buy rating and $60 price target initiated by HC Wainwright & Co. analyst Edwin Zhang on Calliditas Therapeutics (NASDAQ:CALT) is a positive signal for the stock. This recommendation suggests that the analyst believes the stock has significant upside potential, which could lead to increased investor interest and a short-term positive impact on the stock price.